DE69008853D1 - Verwendung eines Derivates des 1,3,7-Trimethylxanthins zur Behandlung von Gedächtnisstörungen, intellektuellen Störungen im Alter, und bei der Alzheimerkrankheit. - Google Patents

Verwendung eines Derivates des 1,3,7-Trimethylxanthins zur Behandlung von Gedächtnisstörungen, intellektuellen Störungen im Alter, und bei der Alzheimerkrankheit.

Info

Publication number
DE69008853D1
DE69008853D1 DE69008853T DE69008853T DE69008853D1 DE 69008853 D1 DE69008853 D1 DE 69008853D1 DE 69008853 T DE69008853 T DE 69008853T DE 69008853 T DE69008853 T DE 69008853T DE 69008853 D1 DE69008853 D1 DE 69008853D1
Authority
DE
Germany
Prior art keywords
disorders
alzheimer
disease
treatment
trimethylxanthine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69008853T
Other languages
English (en)
Other versions
DE69008853T2 (de
Inventor
Annie Kamoun
Elisabeth Mocaer
Gilbert Regnier
Claude Guillonneau
Jacques Duhault
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ADIR SARL
Original Assignee
ADIR SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ADIR SARL filed Critical ADIR SARL
Application granted granted Critical
Publication of DE69008853D1 publication Critical patent/DE69008853D1/de
Publication of DE69008853T2 publication Critical patent/DE69008853T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69008853T 1990-08-10 1990-09-17 Verwendung eines Derivates des 1,3,7-Trimethylxanthins zur Behandlung von Gedächtnisstörungen, intellektuellen Störungen im Alter, und bei der Alzheimerkrankheit. Expired - Fee Related DE69008853T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9010235A FR2665636B1 (fr) 1990-08-10 1990-08-10 Utilisation d'un derive de la trimethyl-1,3,7 xanthine pour le traitement des troubles de la memoire, des troubles intellectuels de la senescence et de la maladie d'alzheimer.

Publications (2)

Publication Number Publication Date
DE69008853D1 true DE69008853D1 (de) 1994-06-16
DE69008853T2 DE69008853T2 (de) 1994-10-13

Family

ID=9399600

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69008853T Expired - Fee Related DE69008853T2 (de) 1990-08-10 1990-09-17 Verwendung eines Derivates des 1,3,7-Trimethylxanthins zur Behandlung von Gedächtnisstörungen, intellektuellen Störungen im Alter, und bei der Alzheimerkrankheit.

Country Status (15)

Country Link
US (1) US5173491A (de)
EP (1) EP0470317B1 (de)
JP (1) JPH0647539B2 (de)
AT (1) ATE105478T1 (de)
AU (1) AU631679B2 (de)
CA (1) CA2026118C (de)
DE (1) DE69008853T2 (de)
DK (1) DK0470317T3 (de)
ES (1) ES2056415T3 (de)
FR (1) FR2665636B1 (de)
HK (1) HK56997A (de)
IE (1) IE65158B1 (de)
NZ (1) NZ235389A (de)
OA (1) OA09464A (de)
ZA (1) ZA907739B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2093403C (en) * 1992-04-08 1999-08-10 Fumio Suzuki Therapeutic agent for parkinson's disease
US5484920A (en) * 1992-04-08 1996-01-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for Parkinson's disease
FR2692784B1 (fr) * 1992-06-24 1995-06-30 Pf Medicament Utilisation de la guanosine, de ses precurseurs et ses derives pour la fabrication de medicaments destines a traiter les deficits fonctionnels cerebraux.
JP2613355B2 (ja) * 1992-09-28 1997-05-28 協和醗酵工業株式会社 パーキンソン氏病治療剤
WO1999012546A1 (fr) * 1997-09-05 1999-03-18 Kyowa Hakko Kogyo Co., Ltd. Remede contre la degenerescence neurale
US6365593B2 (en) 2000-04-12 2002-04-02 Repligen Corporation Methylxanthines in the diagnosis and treatment of autistic disorder
AR039385A1 (es) * 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
SE0302756D0 (sv) * 2003-10-17 2003-10-17 Astrazeneca Ab Novel Compounds
KR20060124615A (ko) * 2003-12-09 2006-12-05 교와 핫꼬 고교 가부시끼가이샤 고차 뇌기능 장애의 예방 및/또는 치료제
SE0402591D0 (sv) * 2004-10-25 2004-10-25 Astrazeneca Ab Novel use
MY140748A (en) * 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
TW200804383A (en) * 2006-06-05 2008-01-16 Astrazeneca Ab New compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2558162B1 (fr) * 1984-01-17 1986-04-25 Adir Nouveaux derives de la xanthine, leurs procedes de preparation et les compositions pharmaceutiques les renfermant
US4755517A (en) * 1986-07-31 1988-07-05 Warner-Lambert Company Derivatives of xanthine, pharmaceutical compositions and methods of use therefor
GB8621870D0 (en) * 1986-09-11 1986-10-15 Beecham Group Plc Active compounds
US4783530A (en) * 1986-11-13 1988-11-08 Marion Laboratories, Inc. 8-arylxanthines
GB8819494D0 (en) * 1988-08-16 1988-09-21 Ucb Sa Use of 2-amino-4-morpholino-6-propyl-1 3 5-triazines for preparation of psychotropic medicaments

Also Published As

Publication number Publication date
DE69008853T2 (de) 1994-10-13
AU631679B2 (en) 1992-12-03
CA2026118A1 (fr) 1992-02-11
ES2056415T3 (es) 1994-10-01
EP0470317B1 (de) 1994-05-11
JPH0495029A (ja) 1992-03-27
AU6322890A (en) 1992-05-14
ZA907739B (en) 1991-07-31
JPH0647539B2 (ja) 1994-06-22
US5173491A (en) 1992-12-22
IE65158B1 (en) 1995-10-04
OA09464A (fr) 1992-11-15
DK0470317T3 (da) 1994-09-19
FR2665636B1 (fr) 1994-10-07
CA2026118C (fr) 1998-07-14
EP0470317A1 (de) 1992-02-12
ATE105478T1 (de) 1994-05-15
NZ235389A (en) 1991-12-23
HK56997A (en) 1997-05-09
FR2665636A1 (fr) 1992-02-14

Similar Documents

Publication Publication Date Title
DE69008853D1 (de) Verwendung eines Derivates des 1,3,7-Trimethylxanthins zur Behandlung von Gedächtnisstörungen, intellektuellen Störungen im Alter, und bei der Alzheimerkrankheit.
DK549189D0 (da) Galanthamin-analoge samt anvendelse af disse til fremstilling af laegemidler til behandling af alzheimer's syge
PT100300B (pt) Derivados de aminas heterociclicas-ciclicas, nomeadamente derivados de benzisoxazole-piperidina
NO179695C (no) Anvendelse av æomega-[4-(2-pyrimidinyl)-1-piperazinylÅalkylå-1H-azol-derivater for fremstilling av medisinske produkter beregnet til behandling av forstyrrelser i kognitive funksjoner
ATE156018T1 (de) Verwendung von igf1 oder igf2 zur herstellung eines medikaments für die behandlung von amyotrophischen lateralsklerose
DE69106237D1 (de) Antimigräne Alkoxypyrimidinderivate.
DE69121561D1 (de) Verwendung von 3-guanidinopropionsäure zur herstellung eines medikaments zur behandlung und prävention von fettsucht
ATE76753T1 (de) Pharmazeutische zusammensetzung zur intranasalen verabreichung, die ghrh, einen cholinergischen agonisten und gegebenenfalls ein gallensalz enthaelt.
DK0826370T3 (da) Lægemiddel indeholdende 2-phenyl-1, 2-benzisoselenazol-3(2H)-on til behandling af Alzheimers sygdom
EP0345247A3 (de) Verwendung von monosubstituierten selenorganischen Verbindungen zur Herstellung eines Arzneimittels sowie daraus hergestelltes Arzneimittel und Verfahren zu seiner Herstellung
DK0411615T3 (da) 4-(N-Substitueret amino)-2-butynyl-1-urinstoffer og -thiourinstoffer og derivater deraf som centralt virkende muscariniske midler
ITRM960360A0 (it) Farmaco a base di un derivato della carnitina per il trattamento del= la demenza di alzheimer in pazienti ad insorgenza precoce della pato= logia.
ES2009689A6 (es) Procedimiento para preparar derivados de 3-piperidina-carbaldehido-oxima.
ATE82850T1 (de) Verwendung von 2-pyrimidinyl-1-piperazinderivaten.
HK1054198A1 (en) Novel use of (R)-(-)-2-Ä5-(4-fluorophenyl)-3-pyridylmethylaminomethylÜ-chromane and its physiologically acceptable salts.
DE3772193D1 (de) Verwendung von pteridinen und/oder purinen oder eines xanthinoxidase-hemmers zur herstellung eines arzneimittels zur behandlung von genetisch bedingten degenerativen netzhauterkrankungen.
DE69300037D1 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
PT95467A (pt) Processo para a preparacao de composicoes farmaceuticas contendo um derivado da 1,3,7-trimetil-xantina apropriadas para o tratamento das perturbacoes da memoria,das perturbacoes intelectuais da senesencia e da doenca de alzheimer
SE8802323D0 (sv) 8alfa-acylaminoergoline, its preparation and pharmaceutical compositions containing it
DE59207086D1 (de) Die Verwendung von 1-(5-Oxohexyl)-3-methyl-7-n-propyl-xanthin in der Gefässchirurgie
Spivak et al. Side effects of trazodone in a geriatric population.
Joh et al. The Treatment of Tibial Shaft Fractures by Closed Kuntscher I-M Nailing
Connell Cephalometric and photogrammetric analysis of LeFort I surgery

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee